Date: 2016-04-28
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at ARVO
Company: RXi Pharmaceuticals (USA - MA)
Product: fluorescent analog of RXI-109
Action
mechanism: RNAi. RXI-109 is a self-delivering RNAi (sd-rxRNA®) compound developed to target connective tissue growth factor (CTGF). RXI-109 is designed to silence connective tissue growth factor (CTGF), which plays a key role in tissue regeneration and repair. RXI-109 is currently being evaluated in two clinical trials. A Phase 1/2 clinical study, RXI-109-1501, is underway to evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases. In addition, a Phase 2 clinical trial, RXI-109-1402, is currently evaluating RXI-109 as a treatment to reduce the recurrence of hypertrophic scars following scar revision surgery. Over 100 subjects have been treated with RXI-109 by intradermal injection in all trials to date. Multiple intradermal injections were well tolerated at all dose levels. RXI-109 was shown to cause a dose-dependent silencing of CTGF messenger RNA and protein levels in the treated areas of the skin compared to placebo and preliminary results from Phase 2a studies indicate a clinical effect on scar appearance.
Disease:
Therapeutic area: Ophtalmological diseases - Dermatological diseases
Country:
Trial details:
Latest
news: * On April 28, 2016, RXi Pharmaceuticals announced that the Company has generated new data demonstrating corneal delivery of a fluorescent analog of RXI-109, the Company's most advanced clinical compound, currently in human clinical trials for dermal scarring and subretinal fibrosis associated with late stage age-related macular degeneration. Topical administration to the eye of the Company's novel self-delivering RNAi (sd-rxRNA®) technology formulated in a gel resulted in delivery throughout the cornea in the presence of a corneal wound in vivo. As previously released, this data will be presented at ARVO on Sunday, May 1, 2016.
